Search

Your search keyword '"Aulmann, Christoph"' showing total 5 results
Start Over Author "Aulmann, Christoph" Language english
5 results on '"Aulmann, Christoph"'

1. Systematic symptom screening in patients with advanced cancer treated in certified oncology centers: results of the prospective multicenter German KeSBa project

Author

Braulke, Friederike, Para, Servet, Alt-Epping, Bernd, Tewes, Mitra, Bäumer, Markus, Haberland, Birgit, Mayer-Steinacker, Regine, Hopprich, Anne, de Wit, Maike, Grabe, Michaela, Bender-Säbelkampf, Sophia, Weßling, Caroline, Aulmann, Christoph, Gerlach, Christina, Regincos, Pascale, Fischer, Ferdinand, Haarmann, Soraya, Huys, Tatjana, Drygas, Sabine, Rambau, Anett, Kiani, Alexander, Schnabel, Astrid, Buhl, Christoph, Seipke, Stefanie, Hiemer, Sonja, Polata, Silke, Meßmann, Maximilian, Hansmeier, Anna, Anastasiadou, Louiza, Letsch, Anne, Wecht, Daniel, Hellberg-Naegele, Matthias, Krug, Utz, Wedding, Ulrich, and van Oorschot, Birgitt

Published
2023
Full Text
View/download PDF

2. Predictive value of FDG-PET in patients with advanced medullary thyroid cancer undergoing vandetanib treatment

Author

Werner, Rudolf, Higuchi, Takahiro, Muegge, Dirk, Javadi, Mehrbod S., Märkl, Bruno, Aulmann, Christoph, Buck, Andreas K., Fassnacht, Martin, Lapa, Constantin, and Kreissl, Michael C.

Subjects
ddc:610
Abstract

Introduction: The prognosis of medullary thyroid carcinoma (MTC) is poor using common chemotherapeutic approaches. However, during the last years encouraging results of recently introduced tyrosine kinase inhibitors (TKI) such as vandetanib have been published. In this study we aimed to correlate the results of \(^{18}\)F-fluorodeoxyglucose ([\(^{18}\)F]FDG) positron emission tomography (PET) imaging with treatment outcome. Methods: Eighteen patients after thyroidectomy with recurrent/advanced MTC lesions receiving vandetanib (300 mg orally/day) could be analysed. A baseline \(^{18}\)F-FDG PET prior to and a follow-up \(^{18}\)F-FDG PET 3 months after TKI initiation were performed. During follow-up, tumor progression was assessed every 3 months including computed tomography according to RECIST. Progression-free survival (PFS) was correlated with the maximum standardized uptake value of \(^{18}\)F-FDG in lymph nodes (SUV(LN)max) or visceral metastases (SUV(MTS)max) as well as with clinical parameters using ROC analysis. Results: Within median 3.6 years of follow-up, 9 patients showed disease progression at median 8.5 months after TKI initiation. An elevated glucose consumption assessed by baseline \(^{18}\)F-FDG PET (SUV(LN)max > 7.25) could predict a shorter PFS (2 y) with an accuracy of 76.5% (SUV(LN)max 2.7) also demonstrated an unfavorable prognosis (accuracy, 85.7%). On the other hand, none of the clinical parameters reached significance in response prediction. Conclusions: In patients with advanced and progressive MTC, tumors with higher metabolic activity at baseline are more aggressive and more prone to progression as reflected by a shorter PFS; they should be monitored more closely. Preserved glucose consumption 3 months after treatment initiation was also related to poorer prognosis.

Published
2017

4. Impact of PD-L1 and KRAS status on the efficacy of nintedanib (NIN) + docetaxel (DOC) following treatment with first-line immune checkpoint inhibitor (ICI) + chemotherapy in patients with adenocarcinoma NSCLC: Analysis of cohort C of the...

Author

Grohé, Christian, Wehler, Thomas, Henschke, Sven, Hammerschmidt, Stefan, Aulmann, Christoph, Krüger, Stefan, Dittrich, Ina, Schuette, Wolfgang, von der Heyde, Eyck, Hanson, Sven, Bajorat, Joerg, and Kaiser, Rolf

Published
2023
Full Text
View/download PDF

5. Predictive Value of 18 F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib.

Author

Werner RA, Schmid JS, Higuchi T, Javadi MS, Rowe SP, Märkl B, Aulmann C, Fassnacht M, Kroiss M, Reiners C, Buck AK, Kreissl MC, and Lapa C

Subjects
Adult, Aged, Aged, 80 and over, Carcinoembryonic Antigen analysis, DNA Mutational Analysis, Disease Progression, Disease-Free Survival, Female, Fluorodeoxyglucose F18, Follow-Up Studies, Humans, Image Processing, Computer-Assisted, Male, Middle Aged, Predictive Value of Tests, Prognosis, Treatment Outcome, Carcinoma, Neuroendocrine diagnostic imaging, Carcinoma, Neuroendocrine drug therapy, Piperidines therapeutic use, Positron Emission Tomography Computed Tomography, Quinazolines therapeutic use, Thyroid Neoplasms diagnostic imaging, Thyroid Neoplasms drug therapy
Abstract

Therapeutic options in advanced medullary thyroid carcinoma (MTC) have markedly improved since the introduction of tyrosine kinase inhibitors (TKIs). We aimed to assess the role of metabolic imaging using 18 F-FDG PET/CT shortly before and 3 mo after initiation of TKI treatment. Methods: Eighteen patients with advanced and progressive MTC scheduled for vandetanib treatment underwent baseline 18 F-FDG PET/CT before and 3 mo after TKI treatment initiation. During follow-up, CT scans were obtained every 3 mo and analyzed according to RECIST. The predictive value for estimating progression-free survival (PFS) and overall survival (OS) was examined by investigating the 18 F-FDG SUV mean/max of the metabolically most active lesion, as well as by analyzing clinical parameters (tumor marker doubling times [calcitonin, carcinoembryonic antigen], prior therapies, rearranged-during-transfection mutational status, and disease type). Results: Within a median follow-up of 5.2 y, 9 patients experienced disease progression after a median interval of 2.1 y, whereas the remainder had ongoing disease control (5 with a partial response and 4 with stable disease). Eight of the 9 patients with progressive disease died from MTC after a median of 3.5 y after TKI initiation. A pretherapeutic SUV mean of more than 4.0 predicted a significantly shorter PFS (1.9 y vs. 5.2 y, P = 0.04). Furthermore, sustained high 18 F-FDG uptake at 3 mo with a SUV mean of more than 2.8 tended to portend an unfavorable prognosis, with a PFS of 1.9 y (vs. 3.5 y, P = 0.3). Prolonged carcinoembryonic antigen doubling times were significantly correlated with longer PFS ( r = 0.7) and OS ( r = 0.76, P < 0.01). None of the other clinical parameters had prognostic significance. Conclusion: Pretherapeutic 18 F-FDG PET/CT provides prognostic information in patients with advanced MTC scheduled for treatment with the TKI vandetanib. A low tumor metabolism with an SUV mean of less than 4.0 before treatment predicts a longer PFS., (© 2018 by the Society of Nuclear Medicine and Molecular Imaging.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results